I have done a cash flow which includes Temcell revenue and it gives a slightly improved cash flow. Bottom line is that MSB has enough of cash to see it through to at least January 2018. With a stronger cash position, it has a better bargaining power with the prospective partners and will secure the best arrangements for the benefit of shareholders rather than going cup in hand begging for a deal if it had limited cash. I think the placement was timely and although there is some dilution, MSB is now better placed to proceed with trials and its day to day operations.
There is still the CHF results to come and I am confident good news is on the way.
Mesoblast cash forecast, page-2
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.065(4.69%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.39 | $1.50 | $1.38 | $7.016M | 4.856M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10425 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 44243 | 5 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |